Dyne Therapeutics, Inc. (DYN) Financials

DYN Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 165.1 million 73.8 million
2023-09-30 205.2 million 53.2 million
2023-06-30 251.4 million 44.5 million
2023-03-31 288.6 million 46.7 million

DYN Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -35.1 million 5.7 million
2023-09-30 -50.8 million 4.9 million
2023-06-30 -55.9 million 4.7 million
2023-03-31 -47.1 million 4.6 million

DYN Net Income

No data available :(

DYN Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 123.1 million - 27.4 million
2023-09-30 157.8 million - 28.2 million
2023-06-30 207.7 million - 29.0 million
2023-03-31 238.2 million - 29.8 million

DYN Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 61.4 million
2023-09-30 61.1 million
2023-06-30 59.8 million
2023-03-31 56.3 million

DYN Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 82000 58.8 million 8.8 million -567001
2023-09-30 167000 55.3 million 7.0 million -
2023-06-30 250000 59.1 million 7.6 million -
2023-03-31 230000 37.5 million 7.9 million -

DYN Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 3.8 million 567000
2023-09-30 - 597000
2023-06-30 - 674000
2023-03-31 - 623000

DYN

Price: $26.08

52 week price:
6.40
30.27

Payout Ratio Range:
19.32%
63.83%

Earnings Per Share: -3.98 USD

P/E Ratio: -6.38

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 169300

Ebitda: 950.0 million

Market Capitalization: 2.2 billion

Average Dividend Frequency: 4

Links: